Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

Growth in the Multiple Myeloma Treatment Armamentarium Diversifies Treatment Strategies

September 2nd 2024

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

Abemaciclib Monotherapy Elicits No Response in Advanced RCC: Where the Field is Headed From Here

August 30th 2024

Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.

Revisit Every OncLive On Air Episode From August 2024

August 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Early Data Show High Responses With Zanubrutinib Plus Venetoclax in Treatment-Naive Del17p/TP53+ CLL/SLL

August 30th 2024

Alessandra Tedeschi, MD, discusses preliminary data from arm D of the SEQUOIA trial evaluating zanubrutinib plus venetoclax in high-risk, untreated CLL/SLL.

Stepwise Approach Helps Ease the Integration of BiTEs Into Community Cancer Centers

August 29th 2024

Courtney Van Houzen, PharmD, discusses key factors to be aware of when implementing bispecific T-cell engager programs into the community setting.

FDA Grants Orphan Drug Designation to NXP800 for ARID1a-Deficient Ovarian Cancers

August 29th 2024

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC

August 29th 2024

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

Dissemination vs Misinformation: Social Media’s Role in the Evolution of Cancer Care

August 28th 2024

As the dissemination of information in oncology is spread using social media platforms, the potential for misinformation remains a key hurdle.

Bispecific Antibody De-Escalation: Varying Dosing Strategies Aim to Improve Safety, Maintain Efficacy in R/R Myeloma

August 27th 2024

Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.

Biomarker-Driven Approaches Could Refine Treatment Selection in RCC

August 26th 2024

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

Time-Limited Bispecific Antibodies Could Represent Next Shift in Myeloma Treatment

August 26th 2024

Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.

CDK4/6 Inhibitors, ADCs, and PI3K Inhibitors Individualize HR+ Breast Cancer Management

August 26th 2024

Shipra Gandhi, MD, discusses the evolution of CDK4/6 inhibitors and ADCs across breast cancer subtypes.

DREAMM-7 and DREAMM-8 Data Support Belantamab Mafodotin–Based Combos in R/R Myeloma

August 24th 2024

Suzanne Trudel, MSc, MD, discusses updated data from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin–based regimens in R/R multiple myeloma.

INV724 Earns FDA Rare Pediatric Disease, Orphan Drug Designations for Neuroblastoma

August 23rd 2024

The FDA has awarded rare pediatric disease designation and orphan drug designation to INV724 for the treatment of neuroblastoma.

Erdafitinib Wins EU Approval for FGFR3+ Unresectable, Metastatic Urothelial Carcinoma

August 23rd 2024

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

Olaparib Monotherapy Elicits Responses in HRR+ Prostate Cancer With High-Risk Biochemical Recurrence

August 22nd 2024

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.

Case Study Highlights an Approach to Adjuvant Treatment in RCC

August 22nd 2024

Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.

Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma

August 21st 2024

Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.

Dr Hernandez-Ilizaliturri on the Use of CAR T-Cell Therapy in R/R Multiple Myeloma

August 19th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Hood on the Association Between BRCA Mutations and Primary Tumor Location in PDAC

August 19th 2024

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.